Physician profile
Daniel Polla
NPI 1326402561
$2,150.46
in general payments reported to CMS, 2019-2025
19 companies · $416 in 2025
The $416 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $156 · 2022: $528 · 2023: $506 · 2024: $545 · 2025: $416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,467.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,467.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $477.73 | 2021-2025 | Rocklatan, Eysuvis, Tryptyr |
| Sun Pharmaceutical Industries INC. | $259.35 | 2023-2025 | Cequa |
| Regeneron Healthcare Solutions, INC. | $200.42 | 2023-2025 | Eylea Hd, Eylea |
| Mallinckrodt Hospital Products INC. | $197.25 | 2021-2024 | Acthar |
| Tarsus Pharmaceuticals, INC. | $196.04 | 2024-2025 | Xdemvy |
| Dompe US, INC. | $109.15 | 2022-2025 | Oxervate |
| Oyster Point Pharma, INC. | $105.62 | 2022-2024 | Tyrvaya |
| Thea Pharma INC. | $103.28 | 2023-2025 | Iyuzeh |
| Bausch & Lomb Americas INC. | $82.67 | 2023-2025 | Vyzulta, Amvisc Plus, Envista Mx60 Iol |
| Biotissue Holdings INC. | $73.00 | 2023-2024 | |
| Eyevance Pharmaceuticals LLC | $68.34 | 2021-2022 | |
| Abbvie INC. | $51.55 | 2023-2025 | |
| Harrow Eye, LLC | $47.03 | 2024 | Vevye |
| Aerie Pharmaceuticals, INC. | $45.78 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $43.70 | 2021-2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $29.81 | 2022 | |
| Apellis Pharmaceuticals, INC. | $28.41 | 2023 | Syfovre |
| Allergan, INC. | $18.95 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $12.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Polla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.